Skip to main content

Oyster Point Pharma, Inc.

OYSTDelisted Jan 3, 2023
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001720725

Oyster Point Pharma, Inc. was delisted on Jan 3, 2023; its insiders filed their last Form 4 on Jan 5, 2023; 53 institutions reported holding it in 13F filings for Q4 2022, worth $189.4M in total; no superinvestor held it.

Holders of 5% or more of OYST

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Oyster Point Pharma, Inc., largest stake first. The change is against the holder's previous filing.

No holder currently reports owning 5% or more of Oyster Point Pharma, Inc. on Schedule 13D or 13G.

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

20 Schedule 13D and 13G filings on Oyster Point Pharma, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on OYST
Filed (ET)FilerFormStakeChangeEvent dateFiling
Feb 14, 2023Paradigm Biocapital Advisors LP13G/AOld format–––SEC
Feb 14, 2023RTW Investments, LP13G/AOld format–––SEC
Feb 14, 2023Point72 Asset Management, L.P.13G/AOld format–––SEC
Jan 13, 2023Versant Venture Capital VI, L.P.13D/AOld format–––SEC
Jan 9, 2023New Enterprise Associates 14, L.P.13D/AOld format–––SEC
Jan 5, 2023InvOpps IV US, L.P.13D/AOld format–––SEC
Dec 21, 2022InvOpps IV US, L.P.13D/AOld format–––SEC
Nov 21, 2022New Enterprise Associates 14, L.P.13D/AOld format–––SEC
Jul 18, 2022Paradigm Biocapital Advisors LP13GOld format–New–SEC
Feb 14, 2022RTW Investments, LP13G/AOld format–––SEC
Feb 14, 2022Point72 Asset Management, L.P.13G/AOld format–––SEC
Feb 4, 2022Wellington Management Group LLP13G/AOld format–––SEC
Jan 13, 2022Versant Venture Capital VI, L.P.13D/AOld format–––SEC
Oct 28, 2021Point72 Asset Management, L.P.13GOld format–New–SEC
Oct 27, 2021Versant Venture Capital VI, L.P.13D/AOld format–––SEC
May 24, 2021Versant Venture Capital VI, L.P.13D/AOld format–––SEC
Apr 5, 2021Versant Venture Capital VI, L.P.13D/AOld format–––SEC
Mar 1, 2021Versant Venture Capital VI, L.P.13D/AOld format–––SEC
Feb 12, 2021RTW Investments, LP13G/AOld format–––SEC
Feb 4, 2021Wellington Management Group LLP13GOld format–New–SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Oyster Point Pharma, Inc. shares.

No Form 144 notices for Oyster Point Pharma, Inc. are on file.